The mean size of the ROI, which was used to analyze perfusion in the CNV area, was 4892 ± 4204 pixels. ICC for MBR was 0.97 (95% confidence interval [CI], 0.91–0.99) at baseline, 0.98 (95% CI, 0.93–0.99) at the 1-week time point, and 0.97 (95% CI, 0.92–0.99) at the 1-month time point, respectively. There was a significant decrease of MBR at 1 week (1 week versus baseline, -26.4 ± 14.4%;
P = 0.027), whereas after 1 month MBR was not significantly different from baseline any longer (1 month versus baseline, -17.7 ± 15.2%;
P = 0.121). CMT showed a progressive decrease that reached statistical significance after 1 month compared to baseline (
P = 0.004). The distribution of percent changes in CMT and MBR from baseline are shown in
Supplementary Figs. 1 and
2. No significant changes were observed for BCVA and OPP (
Table 2). Changes in MBR showed no significant correlation with changes in BCVA (whole follow-up period r = 0.168,
P = 0.422; baseline to 1-week interval r = 0.306,
P = 0.310; baseline to 1-month interval r = 0.126,
P = 0.681; and 1-week to 1-month interval r = -0.245,
P = 0.419). Changes in MBR significantly correlated with changes in CMT in the whole follow-up period (r = 0.511,
P = 0.009), in the baseline to the 1-week interval (r = 0.642,
P = 0.018) and in the baseline to 1-month interval (r = 0.652,
P = 0.016), whereas there was no significant correlation in the 1-week to 1-month interval (r = -0.167,
P = 0.585). Changes in MBR grouped by type of anti-VEGF agent are shown in
Supplementary Fig. 3.